Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

74 results about "Carbetocin" patented technology

Carbetocin (INN, BAN) (brand names Duratocin, Pabal, Lonactene, Depotocin, Comoton, Decomoton), or 1-butanoic acid-2-(O-methy-L-tyrosine)-1-carbaoxytocin, is an oxytocic used in obstetrics to control postpartum hemorrhage and bleeding after giving birth, particularly following Cesarean section. It is an eight amino acid long analogue of oxytocin (a nonapeptide) and has a similar mechanism of action. Carbetocin is an agonist at peripherally expressed oxytocin receptors. It is manufactured by Ferring Pharmaceuticals and is available in Canada and the United Kingdom and many other countries throughout the world, but not in the United States.

Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders

InactiveUS6894026B1Prevent and alleviate symptomInhibit initiation and growthOrganic active ingredientsNervous disorderDiseaseVein
Methods and compositions are provided for prophylaxis and treatment of breast cancer involving administration of a therapeutically effective amount of carbetocin and / or other long-acting oxytocin analogues. 1-Butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin (carbetocin) and / or other long-acting oxytocin analogues are formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to inhibit initiation or growth of breast cancer in the patient. The carbetocin and / or other long-acting oxytocin analogues may also be formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to treat, prevent or alleviate the symptoms of a psychiatric disorder in the patient. Carbetocin may be administered prophylactically or to treat existing conditions in patients by a variety of administration modes, including intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery methods and formulations. Preferably, the carbetocin is administered to a mucosal surface of the patient via intranasal delivery. For this purpose, pharmaceutical compositions are provided for intranasal delivery that incorporate carbetocin in a powder or aqueous formulation for intranasal delivery.
Owner:KYALIN BIOSCI

Synthesis process of carbetocin

The invention provides a synthesis process of carbetocin. The synthesis process comprises the following steps: performing a coupling reaction on Fmoc-Gly-OH with Rink Amide-AM Resin obtained in the first step to obtain Fmoc-Gly-Rink Amide-AM Resin; performing deprotection (20% piperidine) with DBLK to obtain H-Gly-Rink Amide-AM RFesin, and orderly completing the coupling of the H-Gly-Rink Amide-AM Resin with Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH, Fmoc-Tyr(Me)-OH and tetrachlorobutyric acid until carbetocin linear peptide resin is synthesized; mixing a cracking agent with the carbetocin linear peptide resin obtained in the fourth step to have a cracking reaction, thereby removing the Rink Amide-AM Resin and side chain protecting groups; cyclizing the carbetocin linear crude peptide into a carbetocin crude product, and separating and purifying the carbetocin crude product to obtain the carbetocin. The synthesis process has the advantages that the polymerization side reaction is prevented, the process route is greatly simplified, the production cost is reduced and the synthesis efficiency is improved; in addition, the purity of the finished product is high; in short, the synthesis process is convenient for large-scale production, and meanwhile, advantageous for environmental protection, and has remarkable economic and social benefits.
Owner:苏州天马医药集团天吉生物制药有限公司

Process for producing medicament with uterine contraction effect

The invention relates to a process for producing a uterine contraction medicament which uses carbetocin as a main drug. The process comprises a synthesis process and a preparation process. The technical scheme of solid-phase synthesis comprises the following steps of: 1, carrying out deprotection by using amino resin as a vector; 2, connecting carboxyl of Fmoc-Gly-OH with amino of the resin to obtain Fmoc-Gly-amino resin; 3, carrying out solid-phase synthesis sequentially to form sequence residual protection amino acid; 4, removing side-chain protecting groups of cysteine; 5, connecting brombutyl acid onto sulfydryl of cysteine; 6, removing terminal amino Fmoc protection; 7, carrying out solid-phase cyclization; 8, cutting to obtain carbetocin crude peptides; and 9, refining to obtain a carbetocin pure product. The process has the characteristics of simple reaction operation, easy post treatment, high yield, low cost and the like. The invention also discloses a process for preparing a carbetocin freeze-dried powder injection which mainly comprises the following material compositions: carbetocin serving as the main drug, an excipient, a pH (potential of hydrogen) value regulator and water for injection. The powder injection has the advantages of high dispersion degree, high stability and the like.
Owner:SHENZHEN JYMED TECH

Carbetocin pharmaceutical composition and preparation method thereof

The invention relates to a stable pharmaceutical composition containing carbetocin, and a preparation method thereof. The stable pharmaceutical composition containing carbetocin contains carbetocin, a pH regulator, an isoosmotic regulator and pharmaceutically acceptable auxiliary materials. The composition is used for preventing uterine atony and postpartum hemorrhage after selective epidural or spinal anesthesia cesarean section. The pharmaceutical composition mainly exists in a liquid form and is used through parenteral administration forms, mainly injection and nasal spray.
Owner:HYBIO PHARMA

Method for preparing carbetocin

The invention discloses a method for preparing carbetocin. The method comprises the following steps: coupling Fmoc-Cys(Mmt)-OH with hydroxyl function group resin to obtain Fmoc-Cys(Mmt)-resin; removing Fmoc from the Fmoc-Cys(Mmt)-resin to obtain H-Cys(Mmt)-resin; coupling the Fmoc-Asn(Trt)-OH with the H-Cys(Mmt)-resin to obtain Fmoc-Asn(Trt)-Cys(Mmt)-resin; repeating the steps of removing Fmoc and condensation reaction according to a solid-phase synthesis method, so as to obtain peptide resin with a structure shown in A; removing the Fmoc from the A, and then reacting with bromine succinimide butyrate to obtain B; obtaining C from the B in a manner of weak acid cracking; obtaining a segment as shown in a formula D in manners of cyclizing and cracking, and obtaining E from the D by cracking in a strong acid system; mixing the Fmoc-Gly-OH with amino resin and then removing the Fmoc to obtain H-Gly-resin by coupling reaction; repeating the steps according to the solid-phase synthesis method, so as to obtain F; coupling the segment E with the F, so as to obtain the peptide resin in the formula G; and obtaining the carbetocin H after cracking the G. The method disclosed by the invention is high in total yield, less in impurity content, and high in product purity, and has a great industrial prospect.
Owner:HAINAN SHUANGCHENG PHARMA

Preparation method for carbetocin

The invention discloses a preparation method for carbetocin. The preparation method comprises the following steps: subjecting swelled, deprotected and washed amino resin to reacting with an activated protected amino acid solution in a constant-temperature vibrator, carrying out successive introduction into protected amino acids corresponding to first-to-eighth amino acids accounting from the resin and into butyric acid at the tail end of N; subjecting prepared carbetocin precursor peptide 1-amino resin to deprotection, carrying out washing, then carrying out drying until the dried carbetocin precursor peptide 1-amino resin is of a granular shape, adding a cutting reagent, and carrying out a cutting reaction and settling; dissolving a carbetocin precursor peptide II in a solvent, removing impurities by adopting a reversed phase highly-efficient liquid chromatography method, and carrying out liquid-phase cyclizing so as to obtain a crude carbetocin peptide III; and subjecting the crude carbetocin peptide III to purifying and freeze-drying so as to obtain a pure carbetocin polypeptide. The preparation method provided by the invention utilizes an Fmoc solid-phase synthetic principle to develop a solid-phase synthetic technology; and through process optimization, the yield of crude carbetocin is up to 90% or above, so the yield of carbetocin is greatly improved.
Owner:合肥国肽生物科技有限公司

Purifying method for carbetocin

The invention discloses a purifying method for carbetocin. The method employs a purifying scheme of a combination of semi-permeable membrane dialysis purification and reversed phase chromatographic purification to eventually obtain carbetocin with a purity of greater than 99.5%. Semi-permeable membrane dialysis purification is simple to operate and does not need special equipment, and a semi-permeable membrane is repeatedly usable, so cost is reduced. Meanwhile, through preliminary purification by using semi-permeable membrane technology, chromatographic purification can be carried out without concentration, so the step of high-temperature concentration is omitted, the possibility of high-temperature degradation of polypeptide is reduced, and yield and purity are ensured.
Owner:郑州大明药物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products